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Supplementary Methods 
Clinical Samples Analyses: Studies on clinical samples complied with the ethical principles 
stated in the Declarations of Helsinki and were covered by ethical approvals (NHS-NRES 
11SW/0093 and 10/HO107/63, from the Central Bristol Research Ethics Committee). 
Anonymized limb muscle samples (adjacent to the surgical incision) were obtained from patients 
receiving limb amputation for critical limb ischemia (CLI) and from subjects with no peripheral 
vascular disease who were undergoing saphenous vein harvesting in preparation for elective 
coronary artery bypass grafting (non-CLI control). Patient characteristics are reported in the 
online-only Data Supplement (Supplement Table 1). All muscle samples were collected in 
RNALater® RNA stabilization solution (Life Technologies, Paisley, UK), incubated overnight at 
4°C and stored at -80°C, as per the manufacturer’s protocol. 
RNA was isolated using Qiazol and the miRNA extraction kit miRNeasy (Qiagen, Crawley, UK). 
Approximately 50mg of tissue was added to 1ml of Qiazol in a MACS C tube (Miltenyi, Surrey, 
UK). Tissue was homogenised using the program RNA02 of the gentleMACS dissociator 
(Miltenyi). The manufacturer’s protocol was then followed, with the RNA finally eluted in 100µl 
nuclease-free water. RNA concentration was quantified using the NanoDrop-1000 
spectrophotometer (Nanodrop Instruments, Delaware, USA), and then stored at -80°C. For reverse 
transcription, cDNA was synthesised from 500 ng of total RNA using the QuantiTect RT kit 
(Qiagen), as per the manufacturer’s instructions, and included a step to remove genomic DNA. All 
cDNA was stored at -20°C. Quantitative PCR was performed using Power SYBR (Life 
Technologies) with a LightCycler 480 (Roche, St Albans, UK), according to the manufacturer’s 
instructions. Data were normalised to 18S ribosomal RNA as an endogenous housekeeping gene, 
and relative expression was calculated using the 2^-(ΔCT
) method, where ΔCT = test gene CT – 
housekeeping gene CT. 
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Supplementary Table 1 
         
    
Control group 
(n = 11) 
Critical limb ischemia  
group  (n = 11) 
p value 
  Age, years (median and IQR) 67 (64 to 78) 66 (59 to 79) 0.49 
 Male, n (%) 9 (82%) 9 (82%) 1.00 
 Hypertension, n (%) 10 (91%) 8 (73%) 0.27 
 Diabetes, n (%) 3 (27%) 11 (100%) < 0.01 
 Insulin therapy, n (%) 1 (9%) 4 (36%) 0.13 
 Coronary Arterial Disease, n (%) 11 (100%) 8 (73%) 0.06 
 Creatinine, mg/dl (mean ± SEM) 1.12 ± 0.07 1.17 ± 0.16 0.79 
 Chronic Renal Failure, n (%) 3 (27%) 3 (27%) 1.00 
 Statins, n (%) 8 (73%) 4 (36%) 0.09 
 Aspirin, n (%) 10 (91%) 3 (27%) < 0.01 
  Clopidogrel, n (%) 4 (36%) 5 (45%) 0.67 
 
Supplementary Table 1.  Clinical characteristics of patients with or without critical limb 
ischemia. Leftover limb muscle samples from patients undergoing cardiovascular surgery were 
analysed. IQR = interquartile range, SEM = standard error of the mean. p values were calculated 
using Mann-Witney test (for age), unpaired t-test (for creatinine) or the z-test for proportions (for 
all other variables). 
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Supplementary Figures 
 
 
 
 
 
Supplementary Figure 1. Atox1 is expressed in CD31+ endothelial cells and Mac3+ 
macrophages in ischemic hindlimbs. Representative staining for Atox1 (green), Mac3 
(macrophage marker, red), or their colocalization (merge) at day 3, and Atox1 (green), CD31 (EC 
marker, red), or their colocalization (merge) at day 7 after ischemia in gastrocnemius muscles. 
White arrows represent colocalization with Atox1/Mac3 (upper) or Atox1/CD31 (lower).  Bars 
represent 100um.  
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Supplementary Figure 2. Atox1 is increased in ischemic muscles from critical limb ischemia 
patients. Atox1 mRNA expression in limb muscles of patients with and without CLI. Expression 
is given relative to 18S (n=11).   
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Supplementary Figure 3. Atox1 is not involved in cell proliferation in ischemic hindlimbs. A 
and B, Representative staining of BrdU (red) and DAPI (blue) (A) and western analysis for cyclin 
D1 protein expression (B) in non-ischemic and ischemic gastrocnemius muscles at 5 days after 
hindlimb ischemia. In A, scale bars= 20µm.  
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Supplementary Figure 4. Cu importer CTR1 is required for VEGF-induced capillary tube 
formation. HUVECs were transfected with control or CTR1 siRNAs and seeded on Matrigel-
coated plates in culture media containing VEGF for 6 h. Four random fields per well were imaged, 
and representative pictures are shown (Top). Averaged numbers of capillary tube branches, 
branching points, and tube length per field are shown (Bottom).  * p < 0.05. 
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Supplementary Figure 5. Atox1 is required for inflammatory cell recruitment to the ischemic 
sites in vivo  A, Representative images of Mac3 staining in ischemic limbs at day 3 in Atox1 KO 
mice injected with purified recombinant adenoviruses (Ad.Atox1-WT, Ad. LacZ (control), 1x109 
pfu) into the adductor and gastrocnemius muscles at one day prior to surgery. Graphs are summary 
of Mac3+ cells at 2-3 ischemic regions per section (n=4, ** p<0.01 vs. WT. Scale Bars=100 m. 
B, Polyvinyl alcohol sponge was implanted subcutaneously into WT and Atox1 KO mice. 
Representative images for immunostaining for macrophage infiltration (Mac3) in sponges 
harvested on day 21.  Lower panels show quantitative analysis of the number of Mac 3+ cells 
(n=5,* p <0.05). Scale Bars= 50µm. 
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Supplementary Figure 6. Cu importer CTR1 is required for TNF-induced expression of 
adhesion molecules and p47phox in ECs.  HUVECs were transfected with CTR1 or control 
siRNAs for 48 hours.  Cells were then incubated with TNF (10ng/ml) for the time indicated.  The 
mRNA levels of each gene were assessed by quantitative real-time PCR.  Gene analysis is taken 
from 4 samples per group taken from 2 independent experiments with samples run in triplicate. 
*p<0.05, ** p<0.01 and *** p<0.001 vs. untreated control cells. 
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Supplementary Figure 7. Reduced ICAM-1/VCAM-1 expression in Atox1 KO ECs activated 
by TNF and reduced p47phox protein expression in Atox1 KO ischemic tissue.  A, ECs 
isolated from WT and Atox1 KO mice stimulated with TNF for 18 hours were used to measure 
VCAM, ICAM-1 and actin protein expression. Representative blots from 3 different experiments. 
B, Ischemic and non-ischemic tissues of WT and Atox1 KO mice at day 7 were used to measure 
p47phox and actin protein expression. (n=3). ***p<0.001 vs ischemic tissue. 
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Supplementary Figure 8. Atox1 depletion with siRNA does not reduce Nox2 and Nox4 mRNA 
expression in TNF-treated ECs.  HUVECs were transfected with Atox1 or control siRNAs for 
48 hours.  Cells were then incubated with TNF (10ng/ml) for the 3 hrs.  The mRNA levels of 
each gene were assessed by quantitative real-time PCR.  Gene analysis is taken from 3 independent 
experiments.  
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Supplementary Figure 9. Cu importer CTR1 is required for TNF-induced Atox1 nuclear 
translocation in ECs. Immunofluorescence staining of Atox1. HUVECs were transfected with 
Ctr1 or control siRNAs and stimulated with TNF (10 ng/ml) for 30 min. Cells were 
immunostained with anti-Atox1 antibody. Scale bars= 20µm. Percentage of Atox1+ cells in 
nucleus was shown in bottom (n=3).  
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Supplemental Figure 10. A, VEGF does not promote Atox1 translocation to the nucleus in 
ECs.  HUVECs were stimulated with VEGF (20 ng/ml) for indicated time and cells were stained 
with anti-Atox 1 antibody and the nuclear marker, DAPI. In each image, percentage of nuclear 
Atox1 positive cells was calculated from 5 randomized view and the cell images are representative 
of 3 different experiments. B, Atox1 depletion by siRNA has no effects on VEGF-induced 
ICAM1/VCAM1 expression in ECs. Cells transfected with Atox1 or control siRNAs were 
incubated with VEGF (20 ng/ml) for 4 hrs, and VCAM-1 and ICAM-1 protein expression was 
measured by Western analysis. Actin was used for a loading control 
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Supplementary Figure 11. Atox1 depletion by siRNA has no effects on VEGF-induced ROS 
production in ECs. HUVECs transfected with Atox1 or control siRNAs were stimulated with 
VEGF (20ng/ml) for the time indicated. Representative images for DCF fluorescence and DAPI 
staining (blue, nucleus marker) (top) and quantification of fluorescence intensity (bottom) (n=3) 
are shown.  
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Supplementary Figure 12. Hepatocyte growth factor (HGF) and Fibroblast growth factor 
(FGF) do not promote Atox1 translocation to the nucleus in ECs.  HUVECs were stimulated 
with HGF (20 ng/ml) or FGF (10 ng/ml) for 30 min. Cells were immunostained with anti-Atox1 
antibody and the nuclear marker DAP1. Scale bars= 20µm.  
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Supplementary Video 1.  Real-time intravital microscopic analysis of neutrophil rolling and 
adhesion on the TNF-inflamed endothelium of postcapillary venules of cremaster muscle 
in WT and Atox1 KO mice.  TNFα was intrascrotally injected into WT and Atox1 KO mice. At 
three hours after TNFα injection, the cremaster muscle was exposed. Mouse neutrophils were 
monitored in an area of 0.02 mm2 over 5 min in the inflamed cremaster muscle venules by infusion 
of Alexa 647-labeled anti-Gr-1. 10 sec time lapse are shown.  A video of two different mice from 
each group (i.e. WT vs. Atox1 KO) are shown (S1video-WT-1, S1video-WT-2, S1video-KO-1, 
S1video-KO-2). 
 
 
 
 
 
 
 
